Delivery Order SPE2DB24D2106-SPE2DB25FAWJC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,027.13 to DMS Pharmaceutical Group Inc. for Lisdexamfetamine 70 mg capsules (90-count) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents performance at DMS Pharmaceutical Group's facility in Conshohocken, Pennsylvania. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, on August 4, 2025, for the supply of Lisdexamfetamine 30 mg capsules in quantities of 100. This firm fixed-price delivery order, valued at $1,388.47, is set to be completed by August 5, 2025, with performance taking place in Conshohocken, Pennsylvania. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on equal...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on July 24, 2025, for Lisdexamfetamine 30 mg capsules (90-count units) with a ceiling value of $1,191.06. This firm fixed-price delivery order represents a specific pharmaceutical supply requirement under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA, valued at $499,999,999 and valid through November 2026. The place of performance is Conshohocken, Pennsylvania. DMS Pharmaceutical Group...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,070.16 firm fixed-price contract is for the delivery of 100 units of 40 mg lisdexamfetamine capsules. The contract has an ultimate completion date of March 20, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,281.36 firm fixed-price contract is for the delivery of 100 units of the prescription drug lisdexamfetamine 70 mg capsules. The contract has a completion date of July 9, 2025 and does not have a set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery...
- This is a $1,272.52 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 100 units of 60 mg lisdexamfetamine capsules. This order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $2,135.88 award is for the delivery of 100 units of 30mg lisdexamfetamine capsules. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, which allows the agency to issue delivery orders for a wide range of pharmaceutical products,...
- This is a federal contract award by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a delivery order valued at $1,176.64 for the supply of 4567764395 Lisdexamfetamine 50 mg capsules. The contract has a firm fixed-price pricing type and an ultimate completion date of April 2, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,000.98 contract is for the delivery of 4,567,329,296 lisdexamfetamine 20 mg capsules, and has an ultimate completion date of February 21, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,367.72, is for the delivery of 4,567,997,741 units of the prescription drug lisdexamfetamine 20 mg capsules. The delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 held by DMS Pharmaceutical Group with the DLA, which enables the agency to issue delivery...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB25FAWJCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,285.04 to DMS Pharmaceutical Group Inc. for 100 capsules of Lisdexamfetamine 10 mg, a controlled substance commonly prescribed for attention deficit hyperactivity disorder. The contract, issued on September 9, 2025, with a completion date of September 10, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will occur at DMS Pharmaceutical Group's distribution facility in Conshohocken, Pennsylvania. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, valued at $499,999,999 and extending through November 2026. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, distributing prescription medications and medical supplies to Department of Defense healthcare facilities nationwide. The company has maintained consistent federal contract performance since its registration in SAM.gov in 2001 and leverages its small business status to compete effectively in government procurement markets.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/9/25 |